Form D · Biotechnology
QuanDx, Inc.
San Jose, CA · CIK 0001570865
Offering snapshot reported Dec 10, 2015 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 24, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2015 | Initial | $3,000,000 | No comparison | 11 | SEC filing |
| Jan 14, 2014 | Initial | $950,000 | No comparison | 10 | SEC filing |
| Mar 1, 2013 | Initial | $300,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-252818
This filing covers the purchase and sale of Series B2 Preferred Stock and the underlying Common Stock issuable upon conversion of such Preferred Stock.
Source: Form D, filed Dec 10, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peng Cheng | Director |
| Xiaojun Lei | Director, Executive |
| Chunlin Liang | Director |
| Guoliang Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
770 Charcot Avenue
San Jose, CA, 95131
San Jose, CA, 95131